Page last updated: 2024-12-08
grandisin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
grandisin: structure given in first source; a lignan isolated from the bark of Cryptocarya crassinervia; RN given refers to ((2alpha,3beta,4alpha,5beta)-(-))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Related Flora
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Cryptocarya | genus | A plant genus of the family LAURACEAE. Members contain cryptofolione, caryachine, grandisin and other compounds. Some PEUMUS species have been reclassified as CRYPTOCARYA.[MeSH] | Lauraceae | A family of mainly aromatic evergreen plants in the order Laurales. The laurel family includes 2,200 species in 45 genera and from these are derived medicinal extracts, essential oils, camphor and other products.[MeSH] |
Cross-References
ID Source | ID |
---|---|
PubMed CID | 442876 |
CHEBI ID | 5535 |
MeSH ID | M0200758 |
Synonyms (10)
Synonym |
---|
53250-50-3 |
C10622 , |
grandisin |
(2s,3s,4s,5s)-3,4-dimethyl-2,5-bis(3,4,5-trimethoxyphenyl)oxolane |
AC1L9DK8 , |
CHEBI:5535 |
zinc04098808 |
(2s,3s,4s,5s)-3,4-dimethyl-2,5-bis(3,4,5-trimethoxyphenyl)tetrahydrofuran |
Q27106797 |
DTXSID40967805 |
Research Excerpts
Overview
Grandisin is a tetrahydrofuran lignan. It displays important biological properties, such as trypanocidal, anti-inflammatory, cytotoxic, and antitumor activities, suggesting its utility as a potential drug candidate.
Excerpt | Reference | Relevance |
---|---|---|
"(-)-grandisin is a tetrahydrofuran lignan that displays important biological properties, such as trypanocidal, anti-inflammatory, cytotoxic, and antitumor activities, suggesting its utility as a potential drug candidate. " | ( In vitro metabolism of the lignan (-)-grandisin, an anticancer drug candidate, by human liver microsomes. Barth, T; Ferreira, Lde S; Habenschus, MD; Lima Moreira, F; Lopes, NP; Moraes de Oliveira, AR, 2015) | 1.25 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
Class | Description |
---|---|
lignan | Any phenylpropanoid derived from phenylalanine via dimerization of substituted cinnamic alcohols, known as monolignols, to a dibenzylbutane skeleton. Note that while individual members of the class have names ending ...lignane, ...lignene, ...lignadiene, etc., the class names lignan, neolignan, etc., do not end with an "e". |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (17)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (29.41) | 29.6817 |
2010's | 11 (64.71) | 24.3611 |
2020's | 1 (5.88) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 19.33
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.33) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 19 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |